Physician profile
Eric S Madore
NPI 1982678884
$4,903.46
in general payments reported to CMS, 2019-2025
13 companies · $3,930 in 2025
The $3,930 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $112 · 2022: $42.68 · 2025: $3,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,610 · Food and Beverage: $1,144 · Travel and Lodging: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,609.50 |
| Food and Beverage | $1,143.93 |
| Travel and Lodging | $176.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,522.56 | 2025 | |
| Janssen Pharmaceuticals, INC | $289.94 | 2019-2022 | |
| Madrigal Pharmaceuticals | $145.59 | 2025 | Rezdiffra |
| Forte Bio-Pharma LLC | $125.01 | 2025 | Prolate, Nalocet, Tanlor |
| Genentech USA, INC. | $124.35 | 2019 | |
| Allergan, INC. | $123.06 | 2019 | |
| Horizon Therapeutics Plc | $122.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.00 | 2020 | |
| Amgen INC. | $95.86 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $92.22 | 2025 | |
| Mylan Specialty L.P. | $77.28 | 2019 | |
| Abbott Laboratories | $44.25 | 2025 | Infinity |
| Astellas Pharma US INC | $29.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Madore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.